E-Locus - Institutional Repository of the University of Crete - Μελέτη νευροπροστατευτικής δράσης του νευροστεροειδούς δεϋδροεπιανδροστερόνη (DHEA dehydroepiandrosterone) σε μοντέλο διαβητικής αμφιβληστροειδοπάθειας

Home Μελέτη νευροπροστατευτικής δράσης του νευροστεροειδούς δεϋδροεπιανδροστερόνη (DHEA dehydroepiandrosterone) σε μοντέλο διαβητικής αμφιβληστροειδοπάθειας

Results - Details

[Add to Basket]

Identifier

000383273

Title

Μελέτη νευροπροστατευτικής δράσης του νευροστεροειδούς δεϋδροεπιανδροστερόνη (DHEA dehydroepiandrosterone) σε μοντέλο διαβητικής αμφιβληστροειδοπάθειας

Alternative Title

Neuroprotective effect of neurosteroid dehydroepiandrosterone (DHEA) in a model of diabetic retinopathy

Author

Κουλάκης, Εμμανουήλ

Thesis advisor

Θερμού, Κυριακή

Reviewer

Κατερινόπουλος, Χαράλαμπος
Χαραλαμπόπουλος, Ιωάννης

Abstract

Diabetic retinopathy (DR) is the leading cause of blindness in ages over 65, and it’s a result of diabetes. Many biochemical pathways are involved in the pathofysiology of the disease as a result of alterations in cell biochemical environment due to high glucose levels. The three components of DR are slow and progressive neuron cell death (neurodigeneration), inflammation and leakage of blood vessels which cause microanevrisms and creation of new abnormal blood vessels (neovascularization). Today, therapeutics target neovascularization, by destroying abnormal vessels and preventing the formation of new ones. The purposes of this study were to establish a model of DR and research which retinal neurons and in what degree are affected by diabetes. After alterations occurred in the neuronal system, neurosteroid dehydroepiandrosterone (DHEA) was administrated, to study the potential neuroprotective role. The alterations we recorded were approximately 60% loss of dopanimergic amacrine cells, a 40% reduction in the immunoreactivity of NFL, an increase of GFAP immunoreactivity, approximately 50%. Alterations in ONL and whole retinal width were also observed. For the first time, in a in vivo model of DR, DHEA was administrated endoperitoneal (10mg/kg) showing it’s role as a novel neuroprotective target by restoring dopaminergic amacrine cells number and immunoreactivity of GFAP and NFL at control levels, in diabetic retina. More research must take place to investigate the neuroprotective role of DHEA in DR and the pathways that involve. BNN20 and BNN27 are novel DHEA synthetic analogs that also should be tested in DR model. These substances due to their hydrophobic nature can be administrated in the eye with drops (this hypothesys is under investigation in our lab). A therapeutic approach involving neuroprotection and neovascularization would be more efficient, than today treatment which targets neovascularization.

Language

Greek

Subject

Apoptosis

Neuroprotection

Streptozotocin

Διαβητική αμφιβληστροπάθεια

Νευροπροστασία

Στρεπτοζοτοκίνη

Issue date

2014-03-28

Collection